Fortunato Ciardiello

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4009045/publications.pdf

Version: 2024-02-01

367 papers	30,961 citations	7069 78 h-index	5364 164 g-index
375 all docs	375 docs citations	375 times ranked	30675 citing authors

#	Article	IF	Citations
1	Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology/Hematology, 1995, 19, 183-232.	2.0	2,457
2	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncology, The, 2010, 11, 753-762.	5.1	1,915
3	EGFR Antagonists in Cancer Treatment. New England Journal of Medicine, 2008, 358, 1160-1174.	13.9	1,869
4	Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. Journal of Clinical Oncology, 2011, 29, 2011-2019.	0.8	1,713
5	Encorafenib, Binimetinib, and Cetuximab in BRAF V600Eâ€“Mutated Colorectal Cancer. New England Journal of Medicine, 2019, 381, 1632-1643.	13.9	918
6	Chronic inflammation and oxidative stress in human carcinogenesis. International Journal of Cancer, 2007, 121, 2381-2386.	2.3	809
7	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 738-746.	5.1	778
8	Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 692-700.	0.8	686
9	Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer. JAMA Oncology, 2017, 3, 194.	3.4	555
10	KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncology, The, 2011, 12, 594-603.	5.1	522
11	Treatment of gastric cancer. World Journal of Gastroenterology, 2014, 20, 1635.	1.4	508
12	Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. European Journal of Cancer, 2012, 48, 1466-1475.	1.3	506
13	ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Research, 2002, 62, 7284-90.	0.4	463
14	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nature Reviews Clinical Oncology, 2009, 6, 519-527.	12.5	391
15	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncology, The, 2019, 20, 849-861.	5.1	368
16	Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. Journal of Clinical Oncology, 2015, 33, 910-915.	0.8	361
17	Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy. Clinical Cancer Research, 2004, 10, 784-793.	3.2	337
18	Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open, 2016, 1, e000060.	2.0	325

#	Article	IF	Citations
19	A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer. Clinical Cancer Research, 2005, 11, 4741-4748.	3.2	312
20	Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2007, 25, 5225-5232.	0.8	306
21	Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clinical Cancer Research, 2003, 9, 1546-56.	3.2	263
22	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600Eâ€“Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. Journal of Clinical Oncology, 2021, 39, 273-284.	0.8	254
23	Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Nonâ€“small Cell Lung Cancer Cells to Treatment with Gefitinib. Clinical Cancer Research, 2007, 13, 2795-2803.	3.2	248
24	First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Nonâ€“Small-Cell Lung Cancer: The TORCH Randomized Trial. Journal of Clinical Oncology, 2012, 30, 3002-3011.	0.8	229
25	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Modern Pathology, 2015, 28, 1481-1491.	2.9	226
26	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. Cancer Treatment Reviews, 2019, 76, 22-32.	3.4	224
27	Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridizationâ€“Positive/Phospho-Aktâ€“Positive or Never Smoker Patients With Advanced Nonâ€“Small-Cell Lung Cancer: The ONCOBELL Trial. Journal of Clinical Oncology, 2007, 25, 2248-2255.	0.8	218
28	Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy. Journal of Thoracic Oncology, 2015, 10, 1133-1141.	0.5	212
29	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncology, The, 2020, 21, 497-507.	5.1	196
30	Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clinical Cancer Research, 2002, 8, 3250-8.	3.2	195
31	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600Eâ€“Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. Journal of Clinical Oncology, 2019, 37, 1460-1469.	0.8	188
32	The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clinical Cancer Research, 2005, 11, 795-805.	3.2	171
33	Clinical management of metastatic colorectal cancer in the era of precision medicine. Ca-A Cancer Journal for Clinicians, 2022, 72, 372-401.	157.7	167
34	PARP inhibitors in ovarian cancer. Cancer Treatment Reviews, 2019, 73, 1-9.	3.4	158
35	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer Agents. Drugs, 2000, 60, 25-32.	4.9	153
36	ALK inhibitors in the treatment of advanced NSCLC. Cancer Treatment Reviews, 2014, 40, 300-306.	3.4	152

#	Article	IF	Citations
37	Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies. European Journal of Cancer, 2013, 49, 1161-1168.	1.3	151
38	Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitorâ€“resistant human lung adenocarcinoma. Journal of Clinical Investigation, 2011, 121, 1313-1328.	3.9	141
39	Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Antiâ€“Epidermal Growth Factor Receptor Drugs in Human Cancer Cells. Clinical Cancer Research, 2008, 14, 5069-5080.	3.2	139
40	Transformation of an established mouse mammary epithelial cell line following transfection with a human transforming growth factor alpha cDNA. Molecular Carcinogenesis, 1989, 2, 1-11.	1.3	135
41	Key cancer cell signal transduction pathways as therapeutic targets. European Journal of Cancer, 2006, 42, 290-294.	1.3	131
42	Increased TGF-Î± as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFRâ€“MET Interaction and Activation of MET Signaling in Colon Cancer Cells. Clinical Cancer Research, 2013, 19, 6751-6765.	3.2	130
43	Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. Cancer Treatment Reviews, 2017, 53, 61-69.	3.4	118
44	Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study. Journal of Clinical Oncology, 2012, 30, 2861-2868.	0.8	117
45	Rational bases for the development of EGFR inhibitors for cancer treatment. International Journal of Biochemistry and Cell Biology, 2007, 39, 1416-1431.	1.2	115
46	Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study. Journal of Clinical Oncology, 2010, 28, 1181-1189.	0.8	113
47	Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nature Clinical Practice Oncology, 2008, 5, 521-530.	4.3	107
48	Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines. Clinical Cancer Research, 2013, 19, 3508-3519.	3.2	106
49	Prognostic Significance of Epidermal Growth Factor Receptor Expression in Colon Cancer Patients Undergoing Curative Surgery. Annals of Surgical Oncology, 2006, 13, 823-835.	0.7	104
50	Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clinical Cancer Research, 2003, 9, 1566-72.	3.2	104
51	Determination of Molecular Marker Expression Can Predict Clinical Outcome in Colon Carcinomas. Clinical Cancer Research, 2004, 10, 3490-3499.	3.2	103
52	SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer. Clinical Cancer Research, 2015, 21, 4686-4697.	3.2	103
53	Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer, 2004, 100, 270-278.	2.0	100
54	Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development. Oncologist, 2007, 12, 840-849.	1.9	100

#	Article	IF	Citations
55	Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses. JAMA Oncology, 2018, 4, e175245.	3.4	98
56	Differential immunohistochemical detection of transforming growth factor Î±, amphiregulin and CRIPTO in human normal and malignant breast tissues. , 1996, 65, 51-56.		95
57	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. Oncologist, 2019, 24, 1395-1402.	1.9	95
58	The RIÎ± subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-Receptor. Oncogene, 1997, 14, 923-928.	2.6	94
59	EGFR-targeted therapy. Experimental Cell Research, 2011, 317, 2765-2771.	1.2	94
60	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open, 2020, 5, e000911.	2.0	94
61	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World Journal of Gastroenterology, 2016, 22, 6345.	1.4	94
62	Protein Kinase A as Target for Novel Integrated Strategies of Cancer Therapy. Annals of the New York Academy of Sciences, 2002, 968, 139-147.	1.8	93
63	The role of EGFR inhibitors in nonsmall cell lung cancer. Current Opinion in Oncology, 2004, 16, 130-135.	1.1	91
64	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. World Journal of Gastroenterology, 2017, 23, 4675.	1.4	91
65	Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncology, The, 2007, 8, 500-512.	5.1	89
66	Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. Clinical Cancer Research, 2014, 20, 3775-3786.	3.2	89
67	Cripto Enhances the Tyrosine Phosphorylation of Shc and Activates Mitogen-activated Protein Kinase (MAPK) in Mammary Epithelial Cells. Journal of Biological Chemistry, 1997, 272, 3330-3335.	1.6	88
68	Simultaneous blockade of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. Oncogene, 2000, 19, 5863-5871.	2.6	88
69	Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. International Journal of Cancer, 2001, 93, 172-178.	2.3	87
70	ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. International Journal of Cancer, 2002, 98, 463-469.	2.3	87
71	Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opinion on Investigational Drugs, 2002, 11, 755-768.	1.9	86
72	Combining Targeted Therapies and Drugs with Multiple Targets in the Treatment of NSCLC. Oncologist, 2006, 11, 274-284.	1.9	86

#	Article	IF	Citations
73	Novel Toll-Like Receptor 9 Agonist Induces Epidermal Growth Factor Receptor (EGFR) Inhibition and Synergistic Antitumor Activity with EGFR Inhibitors. Clinical Cancer Research, 2006, 12, 577-583.	3.2	86
74	Therapeutic value of EGFR inhibition in CRC and NSCLC: 15â€…years of clinical evidence. ESMO Open, 2016, 1, e000088.	2.0	85
75	Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma. Clinical Cancer Research, 2005, 11, 5639-5644.	3.2	83
76	Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocrine-Related Cancer, 2005, 12, S159-S171.	1.6	82
77	Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. Breast Cancer Research and Treatment, 1995, 35, 293-297.	1.1	81
78	Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multiâ€targeted kinase inhibitors in pimasertibâ€resistant human lung and colorectal cancer cells. International Journal of Cancer, 2013, 133, 2089-2101.	2.3	81
79	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer. JAMA Oncology, 2021, 7, 1529.	3.4	80
80	Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells. Clinical Cancer Research, 2010, 16, 4990-5001.	3.2	79
81	Transforming growth factor-Î± messenger RNA localization in the developing adult rat and human mammary gland by in situ hybridization. Developmental Biology, 1990, 140, 123-131.	0.9	78
82	Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. Oncotarget, 2016, 7, 66595-66605.	0.8	78
83	HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. International Journal of Molecular Sciences, 2018, 19, 3595.	1.8	78
84	Regulation by Estrogen through the 5â€²-Flanking Region of the Transforming Growth Factor Î± Gene. Molecular Endocrinology, 1991, 5, 1955-1963.	3.7	77
85	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resistance Updates, 2007, 10, 81-100.	6.5	74
86	Cooperative Inhibition of Renal Cancer Growth by Anti-Epidermal Growth Factor Receptor Antibody and Protein Kinase A Antisense Oligonucleotide. Journal of the National Cancer Institute, 1998, 90, 1087-1998.	3.0	72
87	Angiogenesis: A Target for Cancer Therapy. Current Pharmaceutical Design, 2004, 10, 11-26.	0.9	72
88	Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation, 2007, 75, 788-799.	1.0	72
89	ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Targeted Oncology, 2013, 8, 55-67.	1.7	72
90	EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes ofÂPatients. Gastroenterology, 2017, 153, 178-190.e10.	0.6	72

#	Article	IF	Citations
91	Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs. Current Oncology Reports, 2018, 20, 76.	1.8	72
92	Role and targeting of anaplastic lymphoma kinase in cancer. Molecular Cancer, 2018, 17, 30.	7.9	71
93	Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 27-37.	1.4	70
94	8-Chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo. Journal of the American College of Cardiology, 2000, 36, 288-293.	1.2	69
95	A novelMDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. International Journal of Cancer, 2000, 88, 804-809.	2.3	68
96	NM23 gene expression correlates with cell growth rate and S-phase. International Journal of Cancer, 1995, 60, 837-842.	2.3	66
97	Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-Î± genes on in vitro transformation of human mammary epithelial cells. Molecular Carcinogenesis, 1992, 6, 43-52.	1.3	65
98	Treatment of Elderly Patients With Nonâ€“Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2015, 16, 325-333.	1.1	65
99	Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota. Neoplasia, 2018, 20, 721-733.	2.3	65
100	TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12468-12473.	3.3	63
101	Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. Clinical Cancer Research, 2015, 21, 2975-2983.	3.2	63
102	The role of amphiregulin in breast cancer. Breast Cancer Research and Treatment, 1995, 33, 103-114.	1.1	62
103	Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase Iâ€“II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer. ESMO Open, 2017, 2, e000132.	2.0	61
104	Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. Cancers, 2020, 12, 819.	1.7	61
105	Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism. Clinical Cancer Research, 2003, 9, 2015-21.	3.2	61
106	Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. Journal of Cellular Physiology, 2006, 208, 344-353.	2.0	59
107	Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncology, 2005, 1, 221-234.	1.1	58
108	Second-Line Treatment of Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 430-440.	0.5	58

#	Article	IF	Citations
109	The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocrine-Related Cancer, 2010, 18, 1-11.	1.6	58
110	Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells. Oncotarget, 2016, 7, 4265-4278.	0.8	58
111	EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. Molecular Cancer Therapeutics, 2019, 18, 845-855.	1.9	58
112	Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. Journal of Experimental and Clinical Cancer Research, 2019, 38, 41.	3.5	57
113	The use of xenograft models for the selection of cancer treatments with the EGFR as an example. Critical Reviews in Oncology/Hematology, 2008, 65, 200-211.	2.0	56
114	Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment. Expert Review of Respiratory Medicine, 2008, 2, 167-178.	1.0	56
115	Treatment of Advanced Nonâ€“Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2014, 15, 173-181.	1.1	56
116	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2020, 19, 256-262.e2.	1.0	56
117	Involvement of Growth Factor Receptors of the Epidermal Growth Factor Receptor Family in Prostate Cancer Development and Progression to Androgen Independence. Clinical Prostate Cancer, 2003, 2, 50-57.	2.1	55
118	AXL is an oncotarget in human colorectal cancer. Oncotarget, 2015, 6, 23281-23296.	0.8	55
119	Implication of the Hedgehog pathway in hepatocellular carcinoma. World Journal of Gastroenterology, 2017, 23, 4330.	1.4	54
120	Stromal influences on transformation of human mammary epithelial cells overexpressingc-myc and SV40T. Journal of Cellular Physiology, 1990, 145, 207-216.	2.0	53
121	Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer. Clinical Cancer Research, 2006, 12, 7099-7107.	3.2	52
122	The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biology and Therapy, 2013, 14, 1143-1146.	1.5	51
123	Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Expert Opinion on Biological Therapy, 2013, 13, 241-255.	1.4	50
124	EGF-related peptides in the pathophysiology of the mammary gland. Journal of Mammary Gland Biology and Neoplasia, 1997, 2, 143-151.	1.0	49
125	Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. Journal of Translational Medicine, 2019, 17, 292.	1.8	49
126	How we treat metastatic colorectal cancer. ESMO Open, 2019, 4, e000813.	2.0	49

#	Article	IF	Citations
127	Combined Targeting of Epidermal Growth Factor Receptor and MDM2 by Gefitinib and Antisense MDM2 Cooperatively Inhibit Hormone-Independent Prostate Cancer. Clinical Cancer Research, 2004, 10, 4858-4864.	3.2	48
128	Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line?. Oncologist, 2009, 14, 137-147.	1.9	48
129	Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: A single institution retrospective analysis. Oncology Reports, 2009, 21, 1023-8.	1.2	48
130	Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. European Journal of Cancer, 2015, 51, 942-949.	1.3	47
131	Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. Clinical Cancer Research, 2003, 9, 866-71.	3.2	47
132	Down-regulation of rîİ± subunit of camp-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-ha-ras and c-erbb-2 proto-oncogenes. International Journal of Cancer, 1993, 53, 438-443.	2.3	46
133	Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. Targeted Oncology, 2011, 6, 133-145.	1.7	46
134	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. Oncologist, 2018, 23, 1178-1187.	1.9	46
135	Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. Cancers, 2019, 11, 399.	1.7	46
136	Site-selective 8-chloroadenosine 3â€²,5â€²-cyclic monophosphate inhibits transformation and transforming growth factor Î± production in Ki-ras-transformed rat fibroblasts. FEBS Letters, 1989, 242, 363-367.	1.3	45
137	Immunotherapy for head and neck cancer: Present and future. Critical Reviews in Oncology/Hematology, 2022, 174, 103679.	2.0	45
138	Improving outcomes in colorectal cancer: Where do we go from here?. European Journal of Cancer, 2013, 49, 2476-2485.	1.3	43
139	Vascular endothelial growth factor and neo-angiogenesis inH. pylori gastritis in humans. Journal of Pathology, 2005, 207, 277-284.	2.1	42
140	Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. Interactive Cardiovascular and Thoracic Surgery, 2011, 12, 420-424.	0.5	42
141	Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials. Journal of Clinical Oncology, 2018, 36, 2585-2592.	0.8	42
142	Detection ofKRASmutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics, 2010, 11, 1169-1179.	0.6	41
143	Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models. Clinical Cancer Research, 2012, 18, 1051-1062.	3.2	41
144	Whatâ€™s New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives. International Journal of Molecular Sciences, 2018, 19, 2659.	1.8	41

#	Article	IF	Citations
145	Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab.. Journal of Clinical Oncology, 2014, 32, 3505-3505.	0.8	41
146	Clinical management of advanced gastric cancer: The role of new molecular drugs. World Journal of Gastroenterology, 2014, 20, 14537.	1.4	41
147	Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Molecular Cancer Therapeutics, 2009, 8, 2546-2558.	1.9	40
148	Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors. PLoS ONE, 2011, 6, e28841.	1.1	40
149	Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. Oncologist, 2016, 21, 292-300.	1.9	40
150	Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab.. Journal of Clinical Oncology, 2014, 32, 3506-3506.	0.8	40
151	EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells. , 1999, 80, 589-594.		39
152	Mini Review. Growth Factors, 2004, 22, 133-139.	0.5	39
153	Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. Molecular Cancer Therapeutics, 2006, 5, 1883-1894.	1.9	39
154	Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. , 2000, 85, 710-715.		38
155	Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model. Clinical Cancer Research, 2007, 13, 6450-6458.	3.2	37
156	ALK inhibitors and advanced non-small cell lung cancer (Review). International Journal of Oncology, 2014, 45, 499-508.	1.4	37
157	BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 461-465.	1.1	37
158	Chemosensitization by Antisense Oligonucleotides Targeting MDM2. Current Cancer Drug Targets, 2005, 5, 51-56.	0.8	36
159	Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience. Cancers, 2019, 11, 1504.	1.7	36
160	Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside. Clinical Epigenetics, 2021, 13, 66.	1.8	36
161	Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells. , 1997, 73, 277-282.		35
162	Antisense strategies targeting protein kinase C: preclinical and clinical development. Seminars in Oncology, 2003, 30, 26-31.	0.8	35

#	Article	IF	Citations
163	p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate. Journal of Surgical Oncology, 2006, 93, 241-252.	0.8	35
164	Current status of targeted therapies in advanced gastric cancer. Expert Opinion on Therapeutic Targets, 2012, 16, S29-S34.	1.5	35
165	Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592094941.	1.4	35
166	Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. Cancer Treatment Reviews, 2020, 86, 102023.	3.4	34
167	Over-expression of the epidermal growth factor receptor in human breast cancer cells fails to induce an Estrogen-independent phenotype. International Journal of Cancer, 1990, 46, 712-718.	2.3	33
168	Synergistic antiâ€proliferative and proâ€apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with antiâ€epidermal growth factor receptor (EGFR) drugs in human cancer cells. Journal of Cellular Physiology, 2008, 216, 698-707.	2.0	33
169	Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells. Scientific Reports, 2018, 8, 5309.	1.6	33
170	Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. Oncotarget, 2017, 8, 23020-23032.	0.8	33
171	An International, Multicenter, Randomized Phase III Study of First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Versus First-Line Cisplatin/Gemcitabine Followed by Second-Line Erlotinib in Advanced Nonâ€“Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics of the TORCH Trial. Clinical Lung Cancer, 2008, 9, 235-238.	1.1	32
172	Infection with a transforming growth factor Î± anti-sense retroviral expression vector reduces thein vitro growth and transformation of a human colon cancer cell line. International Journal of Cancer, 1993, 54, 952-958.	2.3	31
173	Amphiregulin anti-sense oligodeoxynucleotides inhibit growth and transformation of a human colon carcinoma cell line. International Journal of Cancer, 1995, 62, 762-766.	2.3	31
174	Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocrine-Related Cancer, 2005, 12, 1051-1058.	1.6	31
175	Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092521.	1.4	31
176	ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 64, 33-37.	0.4	30
177	HER2 Signaling and Resistance to the Anti-EGFR Monoclonal Antibody Cetuximab: A Further Step toward Personalized Medicine for Patients with Colorectal Cancer. Cancer Discovery, 2011, 1, 472-474.	7.7	30
178	Role of HGFâ€“MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer. Biomedicines, 2014, 2, 345-358.	1.4	30
179	KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment. PLoS ONE, 2011, 6, e29146.	1.1	30
180	Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2014, 23, 809-821.	1.9	29

#	Article	IF	Citations
181	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. ESMO Open, 2018, 3, e000299.	2.0	29
182	Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. Journal of Thoracic Oncology, 2018, 13, 810-820.	0.5	29
183	Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Journal of Cellular Physiology, 2005, 205, 355-363.	2.0	28
184	Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Nonâ€“Small-Cell Lung Cancer in Elderly Patients. Journal of Thoracic Oncology, 2014, 9, 733-737.	0.5	28
185	Cancer- and non-cancer related chronic pain: from the physiopathological basics to management. Open Medicine (Poland), 2019, 14, 761-766.	0.6	28
186	Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC. Journal of Experimental and Clinical Cancer Research, 2019, 38, 178.	3.5	28
187	Expression of Wnt5a Is Downregulated by Extracellular Matrix and Mutated c-Ha-ras in the Human Mammary Epithelial Cell Line MCF-10A. Biochemical and Biophysical Research Communications, 1997, 239, 911-917.	1.0	27
188	Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. Expert Opinion on Emerging Drugs, 2003, 8, 501-514.	1.0	27
189	Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase CÎ² inhibitor, in non-small cell lung cancer cells. Molecular Cancer Therapeutics, 2008, 7, 1698-1707.	1.9	27
190	Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. ESMO Open, 2017, 2, e000177.	2.0	27
191	Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents. Cancers, 2019, 11, 859.	1.7	27
192	Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. Cancer Treatment Reviews, 2021, 97, 102172.	3.4	27
193	Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.. Journal of Clinical Oncology, 2015, 33, 3508-3508.	0.8	27
194	Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. Oncotarget, 2017, 8, 68305-68316.	0.8	27
195	Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Molecular Cancer Therapeutics, 2004, 3, 977-83.	1.9	27
196	Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. Clinical Cancer Research, 2005, 11, 1268-76.	3.2	27
197	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. Frontiers in Immunology, 2022, 13, 804597.	2.2	27
198	Emerging VEGF-receptor inhibitors for colorectal cancer. Expert Opinion on Emerging Drugs, 2013, 18, 25-37.	1.0	26

#	Article	IF	Citations
199	Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives. Frontiers in Endocrinology, 2018, 9, 115.	1.5	26
200	Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study. ESMO Open, 2019, 4, e000536.	2.0	26
201	Response of normal and oncogene-transformed human mammary epithelial cells to transforming growth factor Î²1 (TGF-Î²1): Lack of growth-inhibitory effect on cells expressing the simian virus 40 large-t antigen. International Journal of Cancer, 1994, 56, 736-742.	2.3	25
202	Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 166-170.	1.1	25
203	Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncology Letters, 2015, 9, 1628-1632.	0.8	25
204	Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. Journal of Medicinal Chemistry, 2017, 60, 7447-7458.	2.9	25
205	Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer. ESMO Open, 2020, 5, e000753.	2.0	25
206	Primary cutaneous DLBCL non-GCB type: challenges of a rare case. Open Medicine (Poland), 2020, 15, 119-125.	0.6	25
207	A Randomized Phase II Study of Sorafenib/Gemcitabine or Sorafenib/Erlotinib for Advanced Nonâ€“Small-Cell Lung Cancer in Elderly Patients or Patients with a Performance Status of 2: Treatment Rationale and Protocol Dynamics. Clinical Lung Cancer, 2007, 8, 396-398.	1.1	24
208	Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer, 2012, 76, 269-279.	0.9	24
209	Medical treatment of small cell lung cancer: state of the art and new development. Expert Opinion on Pharmacotherapy, 2013, 14, 2019-2031.	0.9	24
210	Phosphatidylinositol 3-kinase (PI3KÎ±)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells. Oncotarget, 2017, 8, 76479-76491.	0.8	24
211	Use of rituximab in NHL malt type pregnant in IÂ° trimester for two times. Open Medicine (Poland), 2019, 14, 757-760.	0.6	24
212	Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. Future Oncology, 2021, 17, 1977-1985.	1.1	24
213	Gut microbiota correlates with antitumor activity in patients with <scp>mCRC</scp> and <scp>NSCLC</scp> treated with cetuximab plus avelumab. International Journal of Cancer, 2022, 151, 473-480.	2.3	24
214	Differential growth factor expression in transformed mouse NIH-3T3 cells. Journal of Cellular Biochemistry, 1990, 42, 45-57.	1.2	23
215	Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer, 2010, 67, 86-92.	0.9	23
216	Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1830-1844.	0.5	23

#	Article	IF	Citations
217	Metformin in lung cancer: rationale for a combination therapy. Expert Opinion on Investigational Drugs, 2013, 22, 1401-1409.	1.9	23
218	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. European Journal of Cancer, 2020, 138, 1-10.	1.3	23
219	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. Lung Cancer, 2021, 152, 165-173.	0.9	23
220	Transfection with a CRIPTO anti-sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal carcinoma cell line. , 1996, 66, 538-543.		22
221	Antisense Targeting Protein Kinase A Type I as a Drug for Integrated Strategies of Cancer Therapy. Annals of the New York Academy of Sciences, 2003, 1002, 236-243.	1.8	22
222	Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma. BMC Cancer, 2011, 11, 126.	1.1	22
223	Unhealthy diets: a common soil for the association of metabolic syndrome and cancer. Endocrine, 2014, 46, 39-42.	1.1	22
224	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Gut, 2015, 64, 921-928.	6.1	22
225	Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. Expert Opinion on Investigational Drugs, 2012, 21, 949-959.	1.9	21
226	Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. Clinical Cancer Research, 2015, 21, 4153-4164.	3.2	21
227	Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers, 2021, 13, 1941.	1.7	21
228	Induction of multidrug resistance (MDR) by transfection of MCF-10A cell line withc-Ha-ras andc-erbB-2 oncogenes. International Journal of Cancer, 1994, 59, 208-211.	2.3	20
229	Combined targeted therapies in non-small cell lung cancer: a winner strategy?. Current Opinion in Oncology, 2007, 19, 98-102.	1.1	20
230	The Potential Role of Pharmacogenomic and Genomic in the Adjuvant Treatment of Early Stage Non Small Cell Lung Cancer. Current Genomics, 2008, 9, 252-262.	0.7	20
231	Baseline IFN-Î³ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. Scientific Reports, 2020, 10, 17626.	1.6	20
232	Cancer Treatmentâ€“Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy. Current Treatment Options in Oncology, 2021, 22, 45.	1.3	20
233	Growth of cells on a perfluorocarbon-medium interphase: A quantitative assay for anchorage-independent cell growth. In Vitro Cellular & Developmental Biology, 1988, 24, 71-78.	1.0	19
234	Resistance mechanisms of tumour cells to EGFR inhibitors. Clinical and Translational Oncology, 2009, 11, 270-275.	1.2	19

#	Article	IF	Citations
235	Differential diagnosis: retroperitoneal fibrosis and oncological diseases. Open Medicine (Poland), 2019, 15, 22-26.	0.6	19
236	Transformation of mouse mammary epithelial cells with the Ha-rasbut not with theneuoncogene results in a gene dosage-dependent increase in transforming growth factor-Î± production. FEBS Letters, 1989, 250, 474-478.	1.3	18
237	A Randomized Phase II Study of Pemetrexed or RAD001 as Second-Line Treatment of Advanced Nonâ€“Small-Cell Lung Cancer in Elderly Patients: Treatment Rationale and Protocol Dynamics. Clinical Lung Cancer, 2007, 8, 568-571.	1.1	18
238	Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study. Cancer Investigation, 2010, 28, 820-827.	0.6	18
239	Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis. International Journal of Molecular Sciences, 2020, 21, 2814.	1.8	18
240	HER2 amplification as a â€˜molecular baitâ€™ for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.. Journal of Clinical Oncology, 2016, 34, TPS774-TPS774.	0.8	18
241	Cetuximab in the treatment of colorectal cancer. Future Oncology, 2005, 1, 173-181.	1.1	17
242	Antiangiogenic drugs in non-small cell lung cancer treatment. Current Opinion in Oncology, 2006, 18, 151-155.	1.1	17
243	Perspectives in Adjuvant Therapy of Gastric Cancer. Oncology, 2009, 77, 38-42.	0.9	17
244	Novel investigational drugs for gastric cancer. Expert Opinion on Investigational Drugs, 2009, 18, 945-955.	1.9	17
245	Adjuvant Chemoradiotherapy in Patients With Stage III or IV Radically Resected Gastric Cancer. Archives of Surgery, 2010, 145, 233.	2.3	17
246	Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. Journal of Experimental and Clinical Cancer Research, 2019, 38, 236.	3.5	17
247	Epigenetic mechanisms underlying prostate cancer radioresistance. Clinical Epigenetics, 2021, 13, 125.	1.8	17
248	A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Nonâ€“Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. Clinical Lung Cancer, 2015, 16, 57-59.	1.1	16
249	Flow-cytometric detection of the RIÎ± subunit of type I cAMP-dependent protein kinase in human cells. Cytometry, 1994, 15, 73-79.	1.8	15
250	Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consensus. Clinical Colorectal Cancer, 2014, 13, 145-155.	1.0	15
251	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. BMC Cancer, 2016, 16, 339.	1.1	15
252	Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells. Cancers, 2019, 11, 1430.	1.7	15

#	Article	IF	Citations
253	Spectroscopic Characterization and Cytotoxicity Assessment towards Human Colon Cancer Cell Lines of Acylated Cycloartane Glycosides from Astragalus boeticus L.. Molecules, 2019, 24, 1725.	1.7	15
254	Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis. Scientific Reports, 2019, 9, 4986.	1.6	15
255	Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature. ESMO Open, 2019, 4, e000551.	2.0	15
256	Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. Oncotarget, 2017, 8, 67592-67604.	0.8	15
257	Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown?. Journal of Thoracic Disease, 2014, 6, 578-80.	0.6	15
258	Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives. International Journal of Molecular Sciences, 2022, 23, 820.	1.8	15
259	Health-Related Quality of Life in Oral Cancer Patients: Scoping Review and Critical Appraisal of Investigated Determinants. Cancers, 2021, 13, 4398.	1.7	14
260	Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2019, 37, 688-688.	0.8	14
261	Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 15.	3.5	13
262	The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer. Current Pharmaceutical Design, 2012, 18, 6155-6168.	0.9	12
263	Immunotherapy in advanced anal cancer: Is the beginning of a new era?. Cancer Treatment Reviews, 2022, 105, 102373.	3.4	12
264	Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice. Cancers, 2022, 14, 2102.	1.7	12
265	Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass. World Journal of Surgical Oncology, 2007, 5, 42.	0.8	11
266	Emerging mitotic inhibitors for non-small cell carcinoma. Expert Opinion on Emerging Drugs, 2013, 18, 97-107.	1.0	11
267	Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?. Therapeutic Advances in Medical Oncology, 2013, 5, 51-72.	1.4	11
268	Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases. Oncology Reports, 2013, 30, 2992-2998.	1.2	11
269	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). ESMO Open, 2016, 1, e000107.	2.0	11
270	PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?. Frontiers in Oncology, 2020, 10, 782.	1.3	11

#	Article	IF	Citations
271	Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania â€˜Luigi Vanvitelliâ€™. ESMO Open, 2020, 5, e000675.	2.0	11
272	Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients. British Journal of Cancer, 2020, 122, 1782-1790.	2.9	11
273	In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches. Molecular Cancer Therapeutics, 2007, 6, 3091-3100.	1.9	10
274	Mechanisms of resistance to EGFR inhibitors. Targeted Oncology, 2007, 2, 31-37.	1.7	10
275	Emerging drugs targeting PD-1 and PD-L1: reality or hope?. Expert Opinion on Emerging Drugs, 2014, 19, 557-569.	1.0	10
276	30 Immunotherapy in advanced NSCLCâ€”from the â€˜tsunamiâ€™ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). ESMO Open, 2018, 3, e000298.	2.0	10
277	Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. Frontiers in Oncology, 2019, 9, 1289.	1.3	10
278	Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. BMC Cancer, 2021, 21, 549.	1.1	10
279	Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. Clinical Colorectal Cancer, 2021, 20, 227-235.	1.0	10
280	Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy. , 2005, 63, 93-115.		10
281	Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells. Oncotarget, 2018, 9, 19273-19282.	0.8	10
282	Optimizing Anti-EGFR Therapy in Colorectal Cancer. Clinical Cancer Research, 2015, 21, 5415-5416.	3.2	9
283	International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Nonâ€“Small Cell Lung Cancer: Realities and Hopes. Journal of Thoracic Oncology, 2016, 11, 1153-1169.	0.5	9
284	A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. Cancer Research, 2019, 79, 4315-4323.	0.4	9
285	Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know. Lung Cancer, 2003, 41, 15-22.	0.9	8
286	Preoperative treatment of locally advanced esophageal carcinoma. International Journal of Oncology, 2013, 43, 1745-1753.	1.4	8
287	Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells. Oncotarget, 2017, 8, 82773-82783.	0.8	8
288	The role of ras gene expression and transforming growth factor Î± production in the etiology and progression of rodent and human breast cancer. Cancer Treatment and Research, 1991, 53, 107-157.	0.2	8

#	Article	IF	Citations
289	Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population . OncoTargets and Therapy, 2020, Volume 13, 867-876.	1.0	8
290	Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice. Medical Oncology, 2017, 34, 186.	1.2	7
291	Second-Line Treatment Options in Nonâ€“Small-CellÂLung Cancer: Report From anÂInternational Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2018, 19, 301-314.	1.1	7
292	Dual inhibition of TGFÎ² and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. Medical Oncology, 2021, 38, 24.	1.2	7
293	Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification).. Journal of Clinical Oncology, 2013, 31, TPS3648-TPS3648.	0.8	7
294	Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.. Journal of Clinical Oncology, 2019, 37, TPS731-TPS731.	0.8	7
295	Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. Oncotarget, 2017, 8, 57528-57536.	0.8	7
296	Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial. Journal of Experimental and Clinical Cancer Research, 2022, 41, 109.	3.5	7
297	Down-regulation of type I protein kinase A by transfection of human breast cancer cells with an epidermal growth factor receptor antisense expression vector. Breast Cancer Research and Treatment, 1998, 47, 57-62.	1.1	6
298	Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016. ESMO Open, 2016, 1, e000114.	2.0	6
299	Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. Cancers, 2021, 13, 5715.	1.7	6
300	Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data. Journal of Personalized Medicine, 2022, 12, 128.	1.1	6
301	Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. Expert Opinion on Drug Discovery, 2007, 2, 335-348.	2.5	5
302	Critical appraisal of the use of regorafenib in the management of colorectal cancer. Cancer Management and Research, 2013, 5, 49.	0.9	5
303	Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required?. Digestive and Liver Disease, 2017, 49, 197-201.	0.4	5
304	Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. Medical Oncology, 2019, 36, 83.	1.2	5
305	Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. ESMO Open, 2019, 4, e000519.	2.0	5
306	Reduction of RI? Subunit of cAMP-dependent Protein Kinase Expression Induces Growth Inhibition of Human Mammary Epithelial Cells Transformed by TGF-?, c-Ha-ras, and c-erbB-2 Genes. Annals of the New York Academy of Sciences, 1993, 698, 102-107.	1.8	4

#	Article	IF	Citations
307	Zd1839 (Iressaâ„¢): Preclinical Studies and Pharmacology. Tumori, 2002, 88, S155-S157.	0.6	4
308	Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment. Targeted Oncology, 2006, 1, 123-129.	1.7	4
309	Review: The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2009, 1, 5-13.	1.4	4
310	Re: Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2010, 102, 573-573.	3.0	4
311	Durable Complete Radiological Response to Nivolumab in Two Heavily Pretreated Western Elderly Patients With Metastatic Gastric Cancer: A Case Report. Frontiers in Oncology, 2020, 10, 130.	1.3	4
312	Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells. Cancers, 2021, 13, 2339.	1.7	4
313	Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors. Biomedicines, 2021, 9, 1045.	1.4	4
314	Health-related quality of life in the early-access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study.. Journal of Clinical Oncology, 2019, 37, 638-638.	0.8	4
315	Light Alcohol Drinking and the Risk of Cancer Development: A Controversial Relationship. Reviews on Recent Clinical Trials, 2020, 15, 164-177.	0.4	4
316	Treatment of esophagogastric junction carcinoma: An unsolved debate. World Journal of Gastroenterology, 2015, 21, 4427-4431.	1.4	4
317	Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series. Healthcare (Switzerland), 2022, 10, 708.	1.0	4
318	Implications of KRAS mutation status for the treatment of metastatic colorectal cancer. Targeted Oncology, 2009, 4, 311-322.	1.7	3
319	Asymptomatic azygos vein overflow in a young patient with primary mediastinal seminoma. Thoracic Cancer, 2019, 10, 2308-2311.	0.8	3
320	Increased circulating levels of vascular endothelial growth factor C can predict outcome in resectable gastric cancer patients. Journal of Gastrointestinal Oncology, 2019, 10, 314-323.	0.6	3
321	Optimal treatment strategy in KRAS wild type (wt) metastatic colorectal cancer (mCRC): Cetuximab plus FOLFIRI followed by FOLFOX4 with or without cetuximab-The Capri trial from the Gruppo Oncologico Dellâ€™Italia Meridionale (GOIM).. Journal of Clinical Oncology, 2013, 31, e14565-e14565.	0.8	3
322	A Trimodality, Four-Step Treatment including Chemotherapy, Pleurectomy/Decortication and Radiotherapy in Early-Stage Malignant Pleural Mesothelioma: A Single-Institution Retrospective Case Series Study. Cancers, 2022, 14, 142.	1.7	3
323	Capecitabine Plus Weekly Oxaliplatin in Gastrointestinal Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 85-89.	0.6	2
324	Combination of Standard Chemotherapy and Targeted Agents. Journal of Thoracic Oncology, 2007, 2, S19-S23.	0.5	2

#	Article	IF	Citations
325	Novel In Vitro Cancer Models for Optimizing Anti-EGFR Therapies. Clinical Cancer Research, 2018, 24, 727-729.	3.2	2
326	Treatment of Cutaneous Melanoma Harboring SMO p.Gln216Arg Mutation with Imiquimod: An Old Drug with New Results. Journal of Personalized Medicine, 2021, 11, 206.	1.1	2
327	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. Journal of Clinical Oncology, 2015, 33, TPS3634-TPS3634.	0.8	2
328	Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial.. Journal of Clinical Oncology, 2015, 33, 565-565.	0.8	2
329	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. Journal of Clinical Oncology, 2015, 33, TPS789-TPS789.	0.8	2
330	A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer (GC) that responded to platinum-based first-line chemotherapy.. Journal of Clinical Oncology, 2019, 37, TPS173-TPS173.	0.8	2
331	Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis. Frontiers in Oncology, 2022, 12, 813462.	1.3	2
332	The search for optimal response prediction in cancer leads to a personalized approach. Targeted Oncology, 2010, 5, 3-4.	1.7	1
333	Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. Lung Cancer, 2011, 74, 544-548.	0.9	1
334	Reply to S. Debska-Szmich et al. Journal of Clinical Oncology, 2015, 33, 3518-3518.	0.8	1
335	Genetic Landscape of Primary Versus Metastatic Colorectal Cancer: to What Extent Are They Concordant?. Current Colorectal Cancer Reports, 2015, 11, 217-224.	1.0	1
336	Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty. ESMO Open, 2019, 4, e000533.	2.0	1
337	PARALLEL 303: Phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy.. Journal of Clinical Oncology, 2021, 39, 3109-3109.	0.8	1
338	Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity. Current Cancer Therapy Reviews, 2007, 3, 236-241.	0.2	0
339	Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment. Current Cancer Therapy Reviews, 2007, 3, 242-248.	0.2	0
340	Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy. Current Cancer Therapy Reviews, 2007, 3, 117-126.	0.2	0
341	Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors. Current Cancer Therapy Reviews, 2007, 3, 276-283.	0.2	0
342	Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment. Current Cancer Therapy Reviews, 2007, 3, 226-235.	0.2	0

#	Article	IF	Citations
343	Editorial [The Role of Epidermal Growth Factor Receptor (EGFR) Targeting Drugs in the Treatment of Cancer Guest Editor: Fortunato Ciardiello]. Current Cancer Therapy Reviews, 2007, 3, 223-225.	0.2	0
344	Effect of cetuximab in recurrent and refractory squamous cell carcinoma of the head and neck (SCCHN): a case report. Targeted Oncology, 2007, 2, 253-257.	1.7	0
345	Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer. Current Signal Transduction Therapy, 2008, 3, 234-243.	0.3	0
346	Reply to M.J. Rother. Journal of Clinical Oncology, 2011, 29, 4207-4208.	0.8	0
347	Is there a role for maintenance therapy in advanced non-small-cell lung cancer?. Clinical Practice (London, England), 2012, 9, 77-86.	0.1	0
348	Delivery optimization of erlotinib according to toxicity: May clinical practice go beyond research?. Lung Cancer, 2013, 80, 352-353.	0.9	0
349	Reply to V. Lorusso et al. Journal of Clinical Oncology, 2013, 31, 289-290.	0.8	0
350	Management of EGFR-mutant non-small-cell lung cancer patients afterÂfirst-line reversible EGF receptor-tyrosine kinaseÂinhibitors. Lung Cancer Management, 2014, 3, 77-84.	1.5	0
351	Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer. Current Colorectal Cancer Reports, 2014, 10, 279-287.	1.0	0
352	Predictive biomarkers to anti-EGF receptor inhibitors in the treatment of metastatic colorectal cancer. Colorectal Cancer, 2014, 3, 299-308.	0.8	0
353	Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review. Oncology Letters, 2016, 12, 4505-4509.	0.8	0
354	The Cancer Moonshot from a European perspective. Lancet Oncology, The, 2017, 18, e626.	5.1	0
355	Towards the era of precision medicine in metastatic colorectal cancer. ESMO Open, 2020, 5, e000685.	2.0	0
356	Cripto. , 2003, , 330-334.		0
357	Trastuzumab Resistance in Breast Cancer. , 2011, , 51-60.		0
358	Increased circulating levels of VEGF-C to predict outcome in resectable gastric cancer patients.. Journal of Clinical Oncology, 2014, 32, 4080-4080.	0.8	0
359	Combination nab-paclitaxel (Nab-P) plus gemcitabine (G) as first-line treatment in advanced pancreatic cancer (APC): Our experience.. Journal of Clinical Oncology, 2014, 32, e15257-e15257.	0.8	0
360	Safety and tolerability of regorafenib (REG) in Italian patients: Subgroup analysis of the phase III CORRECT study in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, e14613-e14613.	0.8	0

#	Article	IF	Citations
361	Correlation of 12-weeks decrease of CA19.9 with overall response rate (ORR) and progression-free survival (PFS) in advanced pancreatic cancer (APC) patients (pts) treated with first-line nab-paclitaxel (Nab-P) and gemcitabine (G).. Journal of Clinical Oncology, 2014, 32, e15256-e15256.	0.8	0
362	Regional variation in physiciansâ€™ awareness, understanding, and use of personalized medicine in the treatment of cancer and perception of patient (pt) education.. Journal of Clinical Oncology, 2015, 33, 574-574.	0.8	0
363	The pretreatment neutrophil-lymphocyte ratio (NLR) as a predictor of outcome in a cohort of metastatic pancreatic cancer patients treated with nab-paclitaxel and gemcitabine.. Journal of Clinical Oncology, 2015, 33, e15224-e15224.	0.8	0
364	How to incorporate a chemo-free interval into the management of metastatic colorectal cancer. Clinical Advances in Hematology and Oncology, 2020, 18 Suppl 16, 1-24.	0.3	0
365	Why chemo-free treatment intervals can improve care of patients with metastatic colorectal cancer. Clinical Advances in Hematology and Oncology, 2020, 18 Suppl 16, 3-5.	0.3	0
366	A systematic review and meta-analysis of early death (ED) upon immune checkpoint inhibitors (ICI) alone or combined with other non-ICIs treatments as first-line treatment of advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, 2669-2669.	0.8	0
367	Phase III study to compare bevacizumab or cetuximab plus FOLFIRI in patients with advanced colorectal cancer RAS/BRAF wild type (wt) on tumor tissue and RAS mutated (mut) in liquid biopsy: LIBImAb Study.. Journal of Clinical Oncology, 2022, 40, TPS3636-TPS3636.	0.8	0